```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory substance extensively used in thrombosis studies . This monoclonal antibody fragment primarily targets the glycoprotein IIb/IIIa complex on platelets , preventing thrombus development. As a result, it's often investigated as a method to analyze the pathways underlying coagulation and to determine the efficacy of antiplatelet drugs . Availability is typically controlled to research settings.
```
The Abciximab Compound Research: Utilizing C7E3 and 143653-53-6 in Studies
Ongoing investigation into abciximab, a antiplatelet agent, frequently incorporates the monoclonal antigen C7E3 and the substance identified as 143653-53-6. These reagents are instrumental for analyzing abciximab's biological activity, assessing its efficacy in various clinical settings, and elucidating potential predictors of treatment response. Additional study leveraging these precise reagents is expected to provide valuable insights for optimizing clinical applications concerning cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Avenues with Abciximab 143653-53-6 using C7E3
Recent studies indicate that the drug (identified as 143653-53-6) presents significant investigative value, particularly when associated with a C7E3 construct. Initial observations suggested that this pairing could improve clinical results in several heart-related settings. Further investigation is focused on elucidating the specific mode of interaction between Abciximab and C7E3, involving assessment of platelet aggregation and blood vessel safeguarding.
- Ongoing research work aim to optimize administration protocols.
- Laboratory approaches are are being utilized to more assess such hypotheses.
- Patient assessments might be essential to completely evaluate patient effectiveness.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers seeking C7E3 for laboratory research should rigorously evaluate purity and documented parameters . The compound is typically offered as a freeze-dried powder and thorough analytical documentation including identity by mass spectrometry , biological activity assays, website and endotoxin level testing is available. Ensure the manufacturer's CoA outlines acceptable values for impurities and conforms to all quality control criteria .
Research-Grade Abciximab Details & Stock
Acquiring analytical-grade Abciximab, specifically referencing the molecule C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its manufacturer. This antibody is widely utilized in cell-based investigations , particularly those involving platelet clumping and occlusion. Current sources offer this substance in varying quantities , typically ranging from mg to larger bulk quantities . We advise reviewing the report of quality to verify quality and appropriateness for your specific use . Moreover, check the stability date before obtaining to maintain ideal efficacy .
- Standard Purity: >95%
- Preservation Conditions: -20°C or appropriate conditions
- Application : Platelet Clumping Suppression Studies